Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP, Bookman MA.

Gynecol Oncol. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29.

2.

Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.

Husain A, Wang Y, Hanker LC, Ojeda B, Anttila M, Breda E, Vuylsteke P, Pujade-Lauraine E.

Gynecol Oncol. 2016 Sep;142(3):465-70. doi: 10.1016/j.ygyno.2016.05.011. Epub 2016 Jun 25.

PMID:
27184721
3.

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.

Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A.

Gynecol Oncol. 2015 Jan;136(1):37-42. doi: 10.1016/j.ygyno.2014.11.074. Epub 2014 Nov 28.

PMID:
25434635
4.

Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.

Aghajanian C, Goff B, Nycum LR, Wang Y, Husain A, Blank S.

Gynecol Oncol. 2014 Apr;133(1):105-10. doi: 10.1016/j.ygyno.2014.02.003. Epub 2014 Feb 6.

PMID:
24508841
5.

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.

Herzog TJ, Monk BJ, Rose PG, Braly P, Hines JF, Bell MC, Wenham RM, Secord AA, Roman LD, Einstein MH, Drake RD, Childs BH.

Gynecol Oncol. 2014 Mar;132(3):517-25. doi: 10.1016/j.ygyno.2014.01.035. Epub 2014 Jan 27.

PMID:
24476788
6.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR.

J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.

7.
8.

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.

PMID:
22659190
9.

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.

Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA.

Gynecol Oncol. 2015 Oct;139(1):17-22. doi: 10.1016/j.ygyno.2015.07.103. Epub 2015 Jul 26.

10.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.

Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16.

PMID:
26590673
11.

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K, Previs R, Tillmanns T, Kapp DS, Chan JK.

Gynecol Oncol. 2015 Dec;139(3):413-8. doi: 10.1016/j.ygyno.2015.06.041. Epub 2015 Jul 2.

PMID:
26144600
12.

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.

Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group.

Lancet Oncol. 2013 Sep;14(10):1020-6. doi: 10.1016/S1470-2045(13)70363-2. Epub 2013 Aug 13.

PMID:
23948349
13.

Dose-dense approaches to ovarian cancer treatment.

Katsumata N.

Curr Treat Options Oncol. 2015 May;16(5):21. doi: 10.1007/s11864-015-0338-4. Review.

PMID:
25859831
14.

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.

Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA.

Gynecol Oncol. 2008 Aug;110(2):140-5. doi: 10.1016/j.ygyno.2008.04.018. Epub 2008 Jun 13.

PMID:
18554700
15.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
16.

Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.

Hagemann AR, Novetsky AP, Zighelboim I, Gao F, Massad LS, Thaker PH, Powell MA, Mutch DG, Wright JD.

Gynecol Oncol. 2013 Dec;131(3):535-40. doi: 10.1016/j.ygyno.2013.09.032. Epub 2013 Oct 4.

17.

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.

Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga AN, Polee M, Hollema H, van Vugt MA, Schaapveld M, Willemse PH; DoCaCel Study Group.

Ann Oncol. 2012 Nov;23(11):2896-902. doi: 10.1093/annonc/mds107. Epub 2012 Jun 11.

PMID:
22689176
18.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.

Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.

19.

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group.

N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.

20.

Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.

Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S.

Invest New Drugs. 2014 Aug;32(4):729-38. doi: 10.1007/s10637-014-0078-5. Epub 2014 Mar 12.

PMID:
24619298

Supplemental Content

Support Center